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It has been known for many years that group A  streptococci contain antigens 
that are immunologically crossreactive with human  tissues, especially the  myo- 
cardium (1-9). Some of the crossreactive streptococcal antigens are components 
of the cell wall (2,  5,  6) while others have been localized to the cell membrane 
(3, 8, 9). We have previously shown that several streptococcal M proteins, which 
are  the  protective  surface  antigens  of  the  organisms,  contain  epitopes  that 
crossreact  with  sarcolemmal  membrane  proteins  of human  heart  (10,  11).  In 
addition, it has recently been shown that group A  streptococci contain antigens 
that crossreact with myosin (12). 
The  present  study  was  undertaken  to  determine  whether  streptococcal  M 
proteins are immunologically crossreactive with cardiac myosin. We present data 
to show that pepsin-extracted and purified type 5  streptococcal M  protein (pep 
M5) ~ evoked antibodies that crossreacted with cardiac myosin as determined by 
enzyme-linked immunosorbent assays (ELISA).  In ELISA inhibition assays, the 
myosin-crossreactive antibodies  were totally inhibited  by pep  M5  and  partially 
inhibited  by  pep  M6  and  pep  M19  but  not  by  pep  M24.  Furthermore,  the 
crossreactive  antibodies,  which  were  affinity  purified  on  a  myosin-Sepharose 
column, opsonized type 5 streptococci, indicating that the myosin-reactive anti- 
bodies  were  directed  against  protective  determinants  on  the  surface  of  the 
bacteria. 
Materials and Methods 
Extraction  and  Pur~cation  of Streptococcal  M  Proteins.  Types  5,  6,  19,  and  24  M 
proteins were purified from limited peptic digests of whole streptococci as previously 
described (13-16).  The purified proteins (pep M) were judged to be homogeneous by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (13). 
Immunization  of Animals.  Three New  Zealand  White rabbits were immunized each 
with a single injection of 300 ttg of pep M5 emulsified in complete Freund's adjuvant (11, 
13). Serum was obtained before immunization and at 2-wk intervals thereafter. 
Antibody Assays.  M protein-specific and myosin-crossreactive antibodies were detected 
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by  ELISA,  as  previously described  (10,  17,  18).  Rabbit  cardiac  myosin,  myosin  light 
chains, and actin were obtained from Sigma Chemical Co., St. Louis, MO. Human skeletal 
muscle c~-tropomyosin was a generous gift from Dr. A. E. Romero-Herrera (Wayne State 
University, Detroit,  MI).  ELISA inhibition  experiments were performed by incubating 
increasing  concentrations  of antigens  with  a  constant  dilution  of antiserum  and  then 
adding the mixture to the antigen-coated wells (18). 
Opsonic antibodies  were  detected  by in  vitro opsonophagocytic assays, as  reported 
previously (13). The test mixtures consisted of 0.05 ml of a standard suspension of type 5 
streptococci, 0.1  ml test serum, and 0.4  ml whole, heparinized (10  U/ml) blood.  After 
rotating  the  mixture  45  min  at  37°C,  the  percentage  of neutrophils  with  associated 
streptococci (percent opsonization) was estimated by microscopic counts of stained smears. 
Opsonization inhibition assays were performed by preincubating the test serum with 100 
#g pep M5 or myosin for 30 min at 37°C before adding the type 5 organisms (13). 
Affinity Purification of Myosin-specific Antibodies.  Antibodies evoked by pep M5  that 
crossreacted with myosin were affinity purified over a column of myosin covalently linked 
to AH-Sepharose 4B (Pharmacia, Inc., Uppsala, Sweden) by methods previously described 
(10,  11). The myosin-specific antibodies were eluted with 0.2 M glycine/0.2 M NaCI, pH 
2.8, dialyzed against 0.02 M phosphate/0.15 M NaCI, pH 7.4 (PBS) and concentrated to 
the  original  serum  volume by membrane filtration  (YM30  membrane; Amicon  Corp., 
Scientific Systems Div., Lexington, MA). 
Transblot Analyses.  SDS-PAGE of myocardial proteins and myosin was performed on 
continuous gradient gels ranging from 10 to 20% or 7.5-15%. Electrophoresed proteins 
were transferred to nitrocellulose paper (10,  11)  which was cut into vertical strips and 
incubated overnight with pep M5 antiserum diluted  1:100 in 0.05 M Tris/0.15 M NaCl, 
pH  7.4  with  1%  bovine serum  albumin  (Tris-BSA).  Inhibition experiments were per- 
formed by adding pep M proteins (20 ~g/ml) to the diluted antibody before incubating 
with the nitrocellulose strips. In some experiments the pep M5 antiserum was absorbed 
with rabbit cardiac myosin that had been electrophoretically transferred to nitrocellulose 
paper. The horizontal strip containing the myosin heavy chains was cut into small pieces 
(5  ram),  blocked  in  Tris-BSA,  and  incubated  by  constant  rotation  with  the  diluted 
antiserum as above. The absorbed antiserum was then incubated with nitrocellulose strips 
containing electrophoresed proteins from human myocardial tissue obtained at autopsy. 
Myosin Antibodies in Sera from Patients with Acute Rheumatic Fever.  Sera from patients 
with acute rheumatic fever (ARF), their siblings, hospitalized controls with and without 
inflammatory diseases,  and  patients  with  poststreptococcal  glomerulonephritis  (AGN) 
were obtained during a separate study between 1981  and  1984 in the Kingdom of Saudi 
Arabiafl The diagnosis of ARF was based on the modified Jones criteria (19).  Rheumatic 
carditis  was  assumed  to  be absent  if there  were  no cardiac  murmurs,  no evidence of 
pericarditis, and a normal electrocardiogram. ELISA results are reported as the optical 
density of the reaction after incubating each serum with cardiac myosin at a dilution of 
1:400.  Statistical  significance  was  calculated  using  Student's  t  test  for  the  difference 
between means of unpaired samples. 
Results 
Myosin  Crossreactive Antibodies  Evoked  by Pep M5.  Each  of three  rabbits im- 
munized  with  a  single  300  ~g dose  of pep  M5  developed  significant  levels of 
antibody  against  cardiac  myosin  (Table  I).  The  pep  M5-immune  sera  also 
crossreacted with the heterologous antigens pep M6 and pep M 19, but not pep 
M24.  Additional  antigens  that  were  tested  in  ELISA  with  negative  results 
included myosin light chains, actin, and a-tropomyosin (data not shown). 
Because  the  pep  M5  antibodies  crossreacted  with  myosin,  pep  M6,  and  pep 
M 19,  ELISA inhibition experiments were performed with one of the antisera to 
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TABLE  I 
M Protein and Myosin Antibodies Evoked in Rabbits Immunized with Pep M5 
585 
Antiserum 
ELISA titer against: 
Pep M5*  Pep M6*  Pep M19*  Pep M24"  Myosin 
8329  102,400  25,600  6,400  <200  3,200 
8331  25,600  25,600  1,600  <200  800 
8332  25,600  12,800  3,200  <200  1,600 
Preimmune pool  <200  <200  <200  <200  <200 
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FIGURE  1.  M  protein  specificity of myosin-crossreactive antibodies evoked by pep  M5, as 
determined by ELISA inhibition assays. Inhibition of antibody binding to myosin was measured 
with increasing concentrations of myosin (©), pep M5 (O), pep M6 (A), pep MI9 (&), or pep 
M24 (I). The highest concentration of soluble inhibitor was 40 #g/ml. 
determine the M protein specificity of the myosin-crossreactive antibodies (Fig. 
1).  The binding of all  of the myosin-crossreactive antibodies was inhibited by 
pep  M5,  the  immunogen,  and  myosin,  the  solid  phase  test  antigen  (Fig.  1). 
Binding was partially inhibited by pep M6 and pep M19 but not at all by pep 
M24. These data show that pep M5 evokes antibodies that crossreact with cardiac 
myosin; some of the myosin antibodies are inhibited by pep M6 and pep M19, 
indicating that all three M proteins share epitopes with myosin. 
Opsonization  of Type 5 Streptococci by Myosin-crossreactive Antibodies.  To deter- 
mine whether the pep M5 antibodies that crossreacted with myosin were evoked 
by  protective  epitopes  on  the  M  protein  molecule,  opsonization  tests  were 
performed with antibodies that were affinity purified over a  myosin-Sepharose 
column. The myosin-crossreactive antibodies eluted from the column opsonized 
type 5 streptococci (Table II). The opsonization was totally inhibited by pep M5 
and myosin, confirming the specificity of the affinity-purified antibodies. In the 
control experiment, myosin failed to inhibit the opsonization of type 5 strepto- 
cocci by the unfractionated pep  M5 antiserum, indicating that the majority of 
the  antibodies  were  M  protein  specific  and  not  myosin  crossreactive.  These 
results show that at least some of the myosin-crossreactive antibodies evoked by 586  M  PROTEIN  MYOSIN  CROSSREACTIONS 
TABLE  II 
Opsonization of Type 5 Streptococci by Affinity-purified Myosin- 
crossreactive Antibodies 
Percent opsoni- 
Antiserum  Inhibitor  zation of type 5 
streptococci 
8329 (16 wk)  None  100 
Pep M5  4 
Myosin  98 
8329 eluted from myosin  None  98 
Pep M5  2 
Myosin  6 
8329 preimmune  None  0 
FIGURE 2.  M protein specificity of myosin-crossreactive  antibodies  evoked by pep  M5, as 
determined by immunoblot analyses. Purified rabbit cardiac myosin was electrophoresed under 
reducing conditions  on an SDS-polyacrylamide continuous gradient gel, ranging from 10 to 
20%. A portion of the gel was stained with Coomassie Blue (A), and the rest  was transferred 
to nitrocellulose  strips  (B-G). Preimmune rabbit serum  was negative  (B) and the  immune 
serum  reacted  strongly  with  the  heavy  chain  of myosin  (C). The antibodies  were  totally 
inhibited  by pep M5 (D), partially inhibited  by pep M6 (E) and pep M19 (F), and not at all by 
pep M24 (G). 
pep  M5  are directed against  protective epitopes  on the native  type 5  M  protein 
that are exposed on the surface of the organism. 
Transblot  Analyses  of Myosin-crossreactive  Antibodies.  Immunoblot  analyses 
were  performed  to  demonstrate  directly  the  binding  of pep  M5  antibodies  to 
myosin  (Fig.  2).  Purified  rabbit  cardiac  myosin  was  electrophoresed  (Fig.  2A) 
and transferred  to nitrocellulose  strips  (Fig.  2,B-G).  The  preimmune  serum did 
not react  with  myosin (Fig.  2B),  while  the  immune  serum  was strongly reactive 
(Fig.  2C).  Inhibition  studies  showed  that  pep  M5  totally  inhibited  antibody 
binding to the heavy chain of myosin (Fig.  2D).  Although the antiserum  reacted 
weakly  with  one  of the  light  chains  of myosin  (Fig.  2 C),  the  antibody  was  not 
inhibited  by pep  M5.  Pep  M6 and pep  M 19 partially  inhibited  the crossreactive DALE AND  BEACHEY  587 
FIGURE 3.  hnmunoblot  analysis of epitopes  shared  between rabbit  and  human  cardiac 
myosin. SDS-extracted human  myocardial proteins  were  electrophoresed  under reducing 
conditions on an  SDS-polyacrylamide  continuous gradient  gel, ranging  from  7.5  to  15%. 
Multiple protein bands were observed on the stained gel (A). Immunoblot analyses revealed 
that the preimmune serum did not react with human myocardial proteins (B) and the pep M5 
immune serum reacted with several proteins (C). Absorption of the immune serum with rabbit 
myosin removed the antibodies binding to the heavy chain of human myosin but not to several 
other myocardial proteins (D). 
antibodies (Fig.  2,E and F,  respectively), whereas pep  M24  had  no effect (Fig. 
2G). 
To  show  that  rabbit  and  human  cardiac  myosin  both  contain  the  pep  M5- 
crossreactive epitopes,  we performed immunoblots  with  SDS-extracted  human 
myocardial proteins (Fig.  3A).  The preimmune serum did not react with  myo- 
cardial  proteins (Fig.  3B).  As  previously shown  (11),  pep  M5  antibodies cross- 
reacted  with  a  number  of human  heart  proteins  (Fig.  3C).  Absorption  of the 
immune serum with rabbit cardiac myosin removed the antibodies that reacted 
with a  protein equal  in  size to the myosin heavy chain (Mr 230,000)  (Fig.  3D). 
These data indicate that the pep M5-crossreactive epitopes are shared by human 
and rabbit cardiac myosin. In addition, pep M5 antibodies crossreact with several 
other human  myocardial proteins,  and  these  antibodies  were  not absorbed  by 
myosin. 
Myosin Antibodies  in the Sera  of ARF Patients.  The finding that several strep- 
tococcal  M  proteins  contained  epitopes  that  crossreacted  with  cardiac  myosin 
prompted us to test sera from patients with acute rheumatic fever for the presence 
of myosin antibodies.  Controls were sera from healthy siblings of ARF patients, 
unrelated children who were hospitalized at the same time as the ARF patients, 
and  children  with  AGN.  The  ELISA  reaction  against  myosin  of each  serum 
diluted  1:400 was compared for each group (Fig.  4). The mean ELISA reading 
of the sera from ARF patients (Fig. 4A) was 0.56, which was significantly higher 
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FIGURE 4.  Myosin antibodies in sera  from patients with acute rbeumatic fever. Sera were 
diluted 1:400 and the absorbance of the ELISA reaction was recorded for ARF patients (A), 
their healthy siblings (B), hospitalized control patients (C), and patients with AGN (D).  Mean 
values -4- SD are indicated by the bars. Open circles represent ARF patients without clinical 
evidence of carditis. 
AGN patients; the latter resulted in mean readings of 0.31  (P <  0.01),  0.34 (P 
<  0.025), and 0.30 (P <  0.025), respectively. Sera from patients with ARF who 
had no clinical evidence of carditis (Fig. 4A, open circles) all showed values less 
than  the mean for the ARF  group.  Although there was considerable overlap 
between the experimental and control groups,  it is clear that sera from some 
ARF patients showed the highest reactivities with cardiac myosin. 
Discussion 
In  the present  study we have  shown  that  M  proteins  from three  different 
serotypes of group A streptococci contain epitopes that crossreact with cardiac 
myosin. The affinity-purified myosin antibodies opsonized type 5  streptococci, 
indicating that they were directed against protective M protein epitopes on the 
surface of the organism. The pep M5 antibodies reacted with intact myosin in 
ELISA, but not myosin light chains, suggesting that the crossreactive epitopes 
reside in the heavy chain region of the molecule. Western blot analyses showed 
that all of the myosin-crossreactive antibodies were directed against pep M5, but 
not all of the pep M5 heart-crossreactive antibodies were directed against myosin. 
Rabbit myosin absorbed the antibodies directed against human myosin, indicating 
that the M protein-crossreactive epitopes are present in the myosin molecules 
from each species. 
Immunological similarities between group A streptococci and host tissues have 
been  recognized for  many years (1-8).  In  most  of these  studies,  neither the 
streptococcal nor the host tissue antigens responsible for the crossreactions were 
identified. Previous studies in our laboratory (10,  11) have shown that types 5, 
6,  and  19  streptococcal M  proteins crossreacted with  sarcolemmal membrane 
proteins  of human  heart.  Most recently, Krisher  and  Cunningham (12)  have DALE  AND  BEACHEY  589 
described a  murine monoclonal antibody raised against type 5 streptococci that 
crossreacts with myosin. The authors provide evidence that this antibody is not 
reactive with  the surface M  protein.  Thus,  there may be at least two different 
streptococcal  components  capable  of evoking  crossreactive  immunity  against 
myosin:  one,  the  surface  M  protein,  and  the  other,  a  membrane-associated 
antigen (9). 
The  immunological  crossreactions  reported  here  between  myosin  and  M 
protein may be directly related to certain structural similarities between the two 
molecules. Recent determinations of the primary structures of several M proteins 
obtained from different streptococcal serotypes (13-17,  20-25) revealed that a 
common  feature was a  seven residue periodicity with  respect to nonpolar and 
charged amino acids (21, 24). The heptapeptide repeats, which extend through 
the majority of the M protein molecules for which primary structures have been 
determined,  are  characteristic  of alpha-helical  coiled-coil  structures  (25).  The 
primary structure  of the rod region  of myosin, which constitutes ~50%  of the 
heavy chain  (26), also shows heptapeptide  repeats that would predict an alpha- 
helical coiled-coil three-dimensional  structure (26-28).  Thus, a protein derived 
from  a  prokaryote  and  one  derived  from  a  eukaryote,  each  with  seemingly 
unrelated functions, share similar configurations that may be responsible, at least 
in  part,  for  immunological  crossreactions.  An  exhaustive  comparison  of the 
amino acid sequences of the M proteins and myosin heavy chains from mamma- 
lian  muscle  may  reveal  regions  of  primary  structural  homology  that  could 
represent crossreactive epitopes. 
The  significance  of immunological  crossreactions  between group A  strepto- 
cocci and host tissues,  in relation  to the pathogenesis of acute rheumatic  fever 
and  rheumatic  carditis is unknown.  In  the present study we showed that  some 
sera  from  acute  rheumatic  fever patients  reacted  very  strongly  with  cardiac 
myosin.  We  do not  mean  to  imply a  pathologic  role  for  these  crossreactions. 
Previous studies (29-32) have demonstrated heart-reactive antibodies in the sera 
of patients  suffering other forms of myocardial injury.  To our knowledge, the 
reactivity of these antibodies with myosin has not been reported. Further studies 
are necessary to determine  the significance  of myosin-crossreactive antibodies, 
whether they are found in  the sera of patients  with rheumatic  heart disease or 
patients with other forms of myocardial damage.  It is known that many patients 
with ARF have exaggerated  immune  responses (19), and  our data  may simply 
reflect  the  general  immune  status  of the  individual  rather  than  an  abnormal 
immunologic  response  to  myosin  in  particular.  Nonetheless,  we  believe  that 
continued  efforts  to  identify  streptococcal  and  host  tissue  antigens  that  are 
immunologically crossreactive may provide valuable insights into the host-path- 
ogen  relationship  and,  possibly, the pathogenesis of autoimmune  diseases such 
as acute rheumatic fever. 
NU IFI l~DaI'y 
We present evidence that M proteins from three different serotypes of group 
A streptococci share epitopes with cardiac myosin. Rabbit antisera  evoked by a 
purified  fragment  of type  5  M  protein  crossreacted  with  myosin,  but  not  o~- 
tropomyosin,  actin,  or  myosin  light  chains.  In  enzyme-linked  immunosorbent 590  M  PROTEIN  MYOSIN CROSSREACTIONS 
assays,  the  myosin-crossreactive antibodies  were  totally inhibited  by type  5  M 
protein and partially inhibited by types 6 and 19 M proteins. The affinity-purified 
myosin  antibodies  opsonized  type  5  streptococci,  indicating  that  they  were 
directed against protective M  protein epitopes on the surface of the organisms. 
Immunoblot analyses demonstrated the binding of the crossreactive antibodies 
to myosin heavy chains.  Sera from patients with acute rheumatic fever showed 
significantly stronger  reactions with  myosin  than  did  sera  from  their  siblings, 
hospitalized controls, or patients with poststreptococcal glomerulonephritis. 
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